Home » Stocks » IQV

IQVIA Holdings Inc. (IQV)

Stock Price: $248.71 USD 3.34 (1.36%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 47.03B
Revenue (ttm) 12.93B
Net Income (ttm) 607.00M
Shares Out 191.60M
EPS (ttm) 2.10
PE Ratio 118.43
Forward PE 28.57
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $248.71
Previous Close $245.37
Change ($) 3.34
Change (%) 1.36%
Day's Open 246.82
Day's Range 246.52 - 250.20
Day's Volume 585,789
52-Week Range 146.00 - 254.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

IQVIA's (IQV) second-quarter 2021 earnings and revenues increase year over year.

2 days ago - Zacks Investment Research

IQVIA (IQV) delivered earnings and revenue surprises of 2.90% and 5.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

Shares of IQVIA Holdings (NYSE:IQV) fell 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 80.51% over the past year to $2.13, which beat the...

2 days ago - Benzinga

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life...

2 days ago - Business Wire

IQVIA's (IQV) second-quarter 2021 earnings and revenues are expected to have improved year over year.

6 days ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Digital health tools are increasingly having a positive impact on health outcomes. Some are becoming integral parts of mainstream medicine, according to fi...

1 week ago - Business Wire

The coronavirus-driven dependency on technology, increased digitization and growing adoption of the multi-cloud model should help the Zacks Technology Services industry thrive. IQV, STX and BCOR are wel...

Other stocks mentioned: BCOR, STX
1 week ago - Zacks Investment Research

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2021 financial results before the market opens on Tuesday, July 27, 2021. The IQV...

2 weeks ago - Business Wire

The 2020s could be the decade of healthcare stocks. Here are 10 companies and one ETF to watch not just for the remainder of this year, but well beyond.

Other stocks mentioned: CURLF, DHR, GSK, ISRG, JAZZ, LHCG, MRNA ...
2 weeks ago - Kiplinger

IQVIA's (IQV) unique ability to standardize, organize and integrate information through applying sophisticated analytics and global technology infrastructure helps it build a strong client base.

3 weeks ago - Zacks Investment Research

Encouraging yearly guidance and consecutive better-than-expected top- and bottom-line performances has been aiding IQVIA Holdings (IQV) stock.

3 weeks ago - Zacks Investment Research

IQVIA's (IQV) new platform brings benefits such as real-time data management, reduced data-harmonization efforts, reduced time of KPI deployment and improved decision making.

1 month ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics Suite (CDAS), a new SaaS-based clinical data analytics platform that combines structured and un...

1 month ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Q2 Solutions, a leading global clinical trial laboratory services organization and a wholly owned subsidiary of IQVIA, has announced the expansion of its laboratory a...

1 month ago - Business Wire

IQVIA Holdings (IQV) stock is riding on consecutive better-than-expected top- and bottom-line performances, and an encouraging yearly guidance.

1 month ago - Zacks Investment Research

MORRISVILLE, N.C.--(BUSINESS WIRE)--Q2 Solutions, a wholly-owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, today announced a transformative collaboration with Ta...

1 month ago - Business Wire

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Despite the substantial impact of the COVID-19 pandemic on patient care during 2020, the scientific advances in oncology continued, with 3,500 new drugs in...

1 month ago - Business Wire

Consecutive better-than-expected top- and bottom-line performances, along with an encouraging yearly guidance, have been aiding IQVIA Holdings (IQV) stock.

2 months ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a v...

2 months ago - Business Wire

IQVIA (IQV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

2 months ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically hi...

2 months ago - Business Wire

Stock Market Has Quiet Day; Iqvia Setting Up, SM Energy Fizzles, Palantir Still Looks Weak

YouTube video

Stock market has quiet day; Iqvia setting up, SM Energy fizzles, Palantir still looks weak. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, i...

Other stocks mentioned: PLTR, SM
2 months ago - Investors Business Daily

The Benzinga Global Small Cap Conference on May 13 featured presentations from publicly-traded companies and educational segments for investors. Among the featured segments was one from Chris Capre on h...

Other stocks mentioned: ANTM, CI, CVS, HSIC, MDT, UNH
2 months ago - Benzinga

MARIETTA, Ohio--(BUSINESS WIRE)---- $PKTX #AMD--ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions

Other stocks mentioned: PKTX
2 months ago - Business Wire

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announ...

2 months ago - Business Wire

IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.

2 months ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and comm...

2 months ago - Business Wire

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excl...

3 months ago - Business Wire

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, tod...

3 months ago - Business Wire

IQVIA (IQV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 months ago - Zacks Investment Research

IQVIA's (IQV) first-quarter 2021 earnings and revenues increase year over year.

3 months ago - Zacks Investment Research

IQVIA (IQV) delivered earnings and revenue surprises of 17.84% and 7.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA revenue for the first quarter of $3,409 million increased 23.8 percent on a reported basis and 21.4 percent at constant currency

3 months ago - Business Wire

IQVIA's (IQV) first-quarter 2021 earnings and revenues are expected to have improved year over year.

3 months ago - Zacks Investment Research

IQVIA Holdings (IQV) has been benefiting from consecutive better-than-expected top- and bottom-line performances, and encouraging yearly EPS guidance.

3 months ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2021 financial results before the market opens on Thursday, April 22, 2021. The IQ...

3 months ago - Business Wire

IQVIA (IQV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 months ago - Zacks Investment Research

The latest deal is expected to help IQVIA (IQV) strengthen its Research & Development Solutions segment.

3 months ago - Zacks Investment Research

SECAUCUS, N.J. and RESEARCH TRIANGLE PARK, N.C.

Other stocks mentioned: DGX
3 months ago - PRNewsWire

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research ser...

Other stocks mentioned: DGX
3 months ago - Business Wire

IQVIA Holdings (IQV) rises on consistent shareholder-friendly measures and strong healthcare-specific infrastructures. Meanwhile,the company's debt-laden balance sheet is a concern.

4 months ago - Zacks Investment Research

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial ...

4 months ago - Business Wire

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janss...

4 months ago - Business Wire

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will p...

4 months ago - Business Wire

IQVIA (IQV) has a strong healthcare-specific global IT infrastructure, analytics-driven clinical development capabilities and a robust real-world solutions ecosystem.

5 months ago - Zacks Investment Research

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering o...

5 months ago - Business Wire

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced that 140 life science companies in nearly 90 countries have selected Orchestrated Customer Engagement (OC...

5 months ago - Business Wire

IQVIA's (IQV) fourth-quarter 2020 revenues and earnings increase year over year.

5 months ago - Zacks Investment Research

About IQV

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and dissemin... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 9, 2013
CEO
Ari Bousbib
Employees
72,000
Stock Exchange
NYSE
Ticker Symbol
IQV
Full Company Profile

Financial Performance

In 2020, IQVIA Holdings's revenue was $11.36 billion, an increase of 2.44% compared to the previous year's $11.09 billion. Earnings were $279.00 million, an increase of 46.07%.

Financial Statements

Analyst Forecasts

According to 21 analysts, the average rating for IQVIA Holdings stock is "Buy." The 12-month stock price forecast is 261.72, which is an increase of 5.23% from the latest price.

Price Target
$261.72
(5.23% upside)
Analyst Consensus: Buy